GlassScriptPhysician profile
Kerry D Rhodes
NPI 1083697593
$15,545.74
in general payments reported to CMS, 2019-2025
62 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $2,142 · 2021: $2,528 · 2022: $2,643 · 2023: $1,881 · 2024: $2,557 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,499.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,821.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,562.32 | 2019-2025 | |
| Lilly USA, LLC | $1,431.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $799.78 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $733.15 | 2020-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $723.25 | 2019-2024 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $706.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $579.66 | 2019-2025 | Trintellix |
| Allergan, INC. | $524.09 | 2019-2021 | |
| Amgen INC. | $508.50 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $472.79 | 2019-2024 | Xarelto |
| Pfizer INC. | $438.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $407.18 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $379.59 | 2022-2025 | Rexulti, Abilify Maintena |
| Eisai INC. | $362.81 | 2020-2021 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $341.96 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $292.45 | 2019-2022 | |
| Amarin Pharma, INC. | $218.33 | 2019-2021 | |
| Astellas Pharma US INC | $217.77 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $201.97 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $199.45 | 2024-2025 | Rexulti |
| Abbott Laboratories | $187.17 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Biosense Webster, INC. | $171.94 | 2022-2023 | Carto 3 |
| Gilead Sciences, INC. | $157.16 | 2019-2020 | |
| Shockwave Medical, INC | $148.38 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Azurity Pharmaceuticals, INC. | $147.86 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Biohaven Pharmaceutical Holding Company LTD. | $138.96 | 2022 | |
| Abiomed | $131.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $127.67 | 2022-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $104.49 | 2022-2025 | Quviviq, Quviviq |
| Mannkind Corporation | $87.44 | 2019-2022 | |
| Ibsa Pharma INC. | $85.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $85.16 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $80.39 | 2022 | |
| Genentech USA, INC. | $75.22 | 2019 | |
| Corcept Therapeutics | $74.47 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $66.25 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $60.54 | 2020 | |
| Esperion Therapeutics, INC. | $54.38 | 2024-2025 | Nexletol |
| Convatec INC. | $53.68 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $50.70 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.97 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $40.98 | 2022-2025 | |
| Ardelyx, INC. | $40.52 | 2024 | Ibsrela |
| Acerus Pharmaceuticals Corporation | $34.31 | 2022 | |
| Medicure Pharma INC. | $31.36 | 2022 | |
| Alk-Abello, INC | $31.11 | 2024 | Grastek, Odactra, Ragwitek |
| Adlon Therapeutics L.P. | $30.48 | 2020 | |
| Currax Pharmaceuticals LLC | $27.56 | 2023 | Contrave, Nexletol, Nexlizet |
| Circassia INC. | $26.31 | 2019 | |
| Globus Medical, INC. | $24.01 | 2025 | Senza |
| Althera Pharmaceuticals LLC | $22.83 | 2021 | |
| Dexcom, INC. | $22.53 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $22.06 | 2019 | |
| Tolmar, INC. | $21.62 | 2023 | |
| Ironshore Pharmaceuticals INC. | $21.53 | 2024 | |
| Ironwood Pharmaceuticals, INC | $19.22 | 2020 | |
| Shield Therapeutics INC | $18.76 | 2022 | |
| Aytu Biopharma, INC. | $17.26 | 2020 | |
| Nevro Corp. | $13.30 | 2022 | |
| Upsher-Smith Laboratories LLC | $12.08 | 2020 | |
| Rxsight INC | $9.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.